# Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

> Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades at $37.95 (-2.84%) as of 4:02:06 AM EST on Nov 19, 2026, +14.57% over the past month. Market cap is $1.83B, with 7.3 days to cover in short interest.

Canonical: https://massive.com/quote/coag
Data as of: 2026-11-19T09:02:06.875Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$37.95** -1.11 (-2.84%)
As of 4:02:06 AM EST on Nov 19, 2026 · 15-minute delayed
Nasdaq · usd

## Stock performance

How Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | +0.23% |
| 1W | -0.46% |
| 1M | +14.57% |
| YTD | +15.15% |
| 1Y | +15.15% |
| 52-wk range | $23.00 – $55.42 |

From daily closes through Nov 18, 2026.

## Key statistics

Today's trading snapshot for COAG: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $38.61 – $40.28 |
| Open | $39.30 |
| Prev close | $39.06 |
| Volume | 301.26K |
| Market cap | $1.83B |
| Shares out | 46.73M |

## Valuation and profitability ratios

Valuation and profitability ratios for Hemab Therapeutics Holdings, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | — |
| P/B | 4.26 |
| P/FCF | — |
| ROE | -17.3% |
| ROA | -16.8% |
| Debt/Equity | 0.00 |
| Div yield | 0.00% |

As of Nov 18, 2026

## Insider trading

[Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insider trading](https://massive.com/quote/coag/insider-trading.md): open-market Form 4 buys and sells by Hemab Therapeutics Holdings, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Hemab Therapeutics Holdings, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 10, 2026 · [Quarterly earnings](https://massive.com/quote/sec-filings/8-k/earnings-releases.md)
  “On November 10, 2026, Hemab Therapeutics Holdings, Inc. (the "Company") issued a press release announcing the Company's financial results for the quarter ended September 30, 2026.”
- Sep 24, 2026 · Executive compensation change
  “Ms. Walbert will receive annual cash compensation of $40,000 as a member of the Board, additional annual cash compensation of $10,000 as a member of the Audit Committee, annual equity grants in accordance with the non-employee director compensation policy and reimbursement for reasonable travel and out-of-pocket expenses incurred in connection with attending Board and committee meetings.”
- May 11, 2026 · Director departure
  “On May 8, 2026, Laura Tadvalkar, Ph.D., notified Hemab Therapeutics Holdings, Inc. (the "Company") of her decision to resign as a member of the Company's board of directors (the "Board"), effective immediately. Dr. Tadvalkar's resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.”
- May 4, 2026 · Public offering
  “On May 4, 2026, the Company completed its IPO of 19,262,500 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,512,500 additional shares of common stock, at a public offering price of $18.00 per share. The gross proceeds to the Company from the IPO were $346.7 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company.”

## COAG short interest

How heavily COAG is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 7.3 |
| Short interest | 3.31M |
| Avg volume | 451.96K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## COAG news

The latest news and headlines about Hemab Therapeutics Holdings, Inc. Common Stock (COAG).

- [Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress](https://www.globenewswire.com/news-release/2026/07/12/3325841/0/en/Hemab-Therapeutics-Presents-New-Clinical-Data-from-HMB-002-in-Von-Willebrand-Disease-and-Introduces-HMB-003-for-Heavy-Menstrual-Bleeding-at-the-ISTH-2026-Congress.html) · GlobeNewswire Inc. · Jul 12, 2026 · positive sentiment
- [Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares](https://www.benzinga.com/pressreleases/26/05/g52263720/hemab-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-under?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · May 4, 2026 · positive sentiment

## About Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| IPO | $18.00 on May 1, 2026 |

[Hemab Therapeutics Holdings IPO page](https://massive.com/quote/coag/ipo.md)

[Company website](https://www.hemab.com)

## FAQ

### What is the Hemab Therapeutics Holdings, Inc. Common Stock (COAG) stock price today?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is trading at $37.95 (-2.84% on the day) as of 4:02:06 AM EST on Nov 19, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Hemab Therapeutics Holdings, Inc. Common Stock?

Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII…

### What is the short interest in COAG?

As of Oct 30, 2026, COAG has 3.31M shares short and 7.3 days to cover.

### What exchange is COAG listed on?

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

## Live data

Prices here are 15-minute delayed. For real-time COAG quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=COAG`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Hemab Therapeutics Holdings, Inc. Common Stock (COAG) insider trading](https://massive.com/quote/coag/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
